ZA964681B - Methods for minimizing bone loss. - Google Patents

Methods for minimizing bone loss.

Info

Publication number
ZA964681B
ZA964681B ZA9604681A ZA964681A ZA964681B ZA 964681 B ZA964681 B ZA 964681B ZA 9604681 A ZA9604681 A ZA 9604681A ZA 964681 A ZA964681 A ZA 964681A ZA 964681 B ZA964681 B ZA 964681B
Authority
ZA
South Africa
Prior art keywords
methods
bone loss
minimizing bone
minimizing
loss
Prior art date
Application number
ZA9604681A
Other languages
English (en)
Inventor
George Joseph Cullinan
Steven Anthony Fontana
Robin Sharon Lee Fuchs-Young
Andrew Lawrence Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA964681B publication Critical patent/ZA964681B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA9604681A 1995-06-06 1996-06-05 Methods for minimizing bone loss. ZA964681B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47111195A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
ZA964681B true ZA964681B (en) 1997-12-05

Family

ID=23870302

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604681A ZA964681B (en) 1995-06-06 1996-06-05 Methods for minimizing bone loss.

Country Status (27)

Country Link
EP (1) EP0747056B1 (fr)
JP (1) JP2001501907A (fr)
KR (1) KR19990022497A (fr)
CN (1) CN1239429A (fr)
AR (2) AR003002A1 (fr)
AT (1) ATE187643T1 (fr)
AU (1) AU696927B2 (fr)
BR (1) BR9608390A (fr)
CA (1) CA2223174A1 (fr)
CO (1) CO4700447A1 (fr)
CZ (1) CZ383097A3 (fr)
DE (1) DE69605600T2 (fr)
DK (1) DK0747056T3 (fr)
EA (1) EA199800014A1 (fr)
ES (1) ES2142545T3 (fr)
GR (1) GR3032863T3 (fr)
HU (1) HUP9900854A3 (fr)
IL (1) IL118573A (fr)
NO (1) NO975560L (fr)
PE (1) PE2298A1 (fr)
PL (1) PL323941A1 (fr)
PT (1) PT747056E (fr)
SI (1) SI0747056T1 (fr)
TR (1) TR199701508T1 (fr)
WO (1) WO1996039141A1 (fr)
YU (1) YU34296A (fr)
ZA (1) ZA964681B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5558498A (en) * 1996-11-22 1998-06-22 Akzo Nobel N.V. Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri

Also Published As

Publication number Publication date
EP0747056A2 (fr) 1996-12-11
WO1996039141A1 (fr) 1996-12-12
AR003134A1 (es) 1998-07-08
DE69605600T2 (de) 2000-05-31
CO4700447A1 (es) 1998-12-29
JP2001501907A (ja) 2001-02-13
HUP9900854A3 (en) 2000-03-28
TR199701508T1 (xx) 1998-03-21
AU5981696A (en) 1996-12-24
AU696927B2 (en) 1998-09-24
EA199800014A1 (ru) 1998-06-25
KR19990022497A (ko) 1999-03-25
PT747056E (pt) 2000-05-31
NO975560D0 (no) 1997-12-02
CA2223174A1 (fr) 1996-12-12
NO975560L (no) 1998-01-26
EP0747056A3 (fr) 1997-03-05
BR9608390A (pt) 1999-05-04
IL118573A (en) 2000-01-31
PL323941A1 (en) 1998-04-27
EP0747056B1 (fr) 1999-12-15
YU34296A (en) 1999-11-22
CZ383097A3 (cs) 1998-09-16
DE69605600D1 (de) 2000-01-20
ES2142545T3 (es) 2000-04-16
ATE187643T1 (de) 2000-01-15
AR003002A1 (es) 1998-05-27
SI0747056T1 (en) 2000-06-30
DK0747056T3 (da) 2000-05-01
GR3032863T3 (en) 2000-07-31
IL118573A0 (en) 1996-10-16
CN1239429A (zh) 1999-12-22
HUP9900854A2 (hu) 1999-08-30
PE2298A1 (es) 1998-02-28

Similar Documents

Publication Publication Date Title
ZA963694B (en) Methods for inhibiting bone loss.
PH31315A (en) Methods for inhibiting bone loss using substitutedbenzothiophene.
ZA967315B (en) Biphenylamides.
MX213417B (es) Fenilpiridazinonas.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA964778B (en) Methods for minimizing bone loss.
DE69610844D1 (en) Hydroformylierungsverfahren.
AU5743396A (en) Methods for inhibiting bone loss
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA966399B (en) Endothelin-receptor-antagonists.
AU5743696A (en) Methods for inhibiting bone loss
ZA964681B (en) Methods for minimizing bone loss.
ZA9710349B (en) Process for making benzisothiazolin-3-ones.
ZA966750B (en) Halogenobenzimidazoles.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA9610053B (en) Process for preparing dioxoazabicyclohexanes.
ZA9610458B (en) Novel method.
ZA967314B (en) Carbamoylcarboxamides.
ZA971775B (en) Novel method.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols
HK1016577A1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
SI0874814T1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
ZA966114B (en) Scatterpile pusher.